Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The book gives an overview on the progress that has been made in the treatment of acute lymphoblastic leukemia (ALL), of acute and chronic myeloid leukemia (AML, CML) and of juvenile myelomonocytic leukemia (JMML). Leukemia is the most common malignant disease in children, and 80% of patients are diagnosed with ALL and 15–20% with AML, whereas CML and JMML are rather rare. Although ALL was considered an incurable disease until the early 1960s, with the availability of cytotoxic drugs and the start of clinical multicenter studies, ALL has become an almost curable disease with a survival rate exceeding 90 % in high-income countries. These impressive results have mainly been achieved by a deeper understanding of the genomic landscape of the disease and the introduction of risk stratifications based on genetic features and response to chemotherapy as determined by the presence or absence of minimal residual disease (MRD). Immunotherapies including bispecific T-cell Engagers (BiTEs), Chimeric Antigen Receptor (CAR) T cells, monoclonal antibodies and improvements in the outcome of allogeneic stem cell transplantation (HSCT) have shown impressive results in chemorefractory or relapsed patients, and it is anticipated that the cure rate can be further increased. For countries with less resources, therapies have to be adapted to increase survival as well. This book also updates on the progress made in the treatment of AML. As in ALL, risk classification based on genetic factors and response to chemotherapy is most important for therapy guidance. The book also provides updates and guidance for the treatment of CML and JMML.

Research & information: general --- Chemistry --- acute lymphoblastic leukemia --- pediatric --- advances --- diagnosis --- treatment --- immunotherapy --- bispecific T-cell engager (BiTE) --- BCP-ALL --- leukemia --- TRAIL --- antibody --- Fc-engineering --- xenograft --- CD19 --- juvenile myelomonocytic leukemia --- RAS signaling --- hematopoietic stem cell transplantation --- 5-azacitidine --- myelodysplastic/myeloproliferative disorders --- targeted therapy --- ADC --- antibody–drug conjugate --- pediatric leukemia --- ALL --- AML --- allogeneic stem cell transplantation --- acute myeloid leukemia --- minimal residual disease --- conditioning regimen --- alternative donors --- B-ALL --- DUX4 --- IKZF1 --- PAX5 --- Ph-like --- ZNF384 --- NUTM1 --- T-ALL --- NOTCH1 --- BCL11B --- transcriptome --- genome --- chronic myeloid leukemia --- CML --- tyrosine kinase inhibitor --- immunizations --- COVID-19 --- childhood acute lymphoblastic leukemia --- low-risk ALL --- risk-stratified treatment --- treatment related toxicity --- L-asparaginase --- acute pancreatitis --- polymorphism --- SNV --- ABCC4 --- CFTR --- other extramedullary relapse --- lymphoblastic leukemia --- children --- prognosis --- evolution of CAR T cells --- FDA-approved CAR products --- TcR versus CAR --- limitations and complications of CAR T cell therapy --- future directions of CAR T cell therapy --- n/a --- antibody-drug conjugate

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Five years of Separations are celebrated by a collection of ten feature articles: one review and nine research articles on topics of current interest. Applications of Gas Chromatography for the Analysis of Tricyclic Antidepressants in Biological Matrices are presented focusing on novel extraction techniques and novel materials used for sample preparation due to the great demand for method development for the determination of TCAs in biofluids, especially for therapeutic drug monitoring. Original research articles include the following: 1. Insights into the Mechanism of Separation of Bisphosphonates by Zwitterionic Hydrophilic Interaction Liquid Chromatography: Application to the Quantitation of Risedronate in Pharmaceuticals. 2. A method based on micro-matrix solid-phase dispersion (μ-MSPD) followed by gas-chromatography tandem mass spectrometry (GC–MS/MS), developed to analyze UV filters in personal care products. 3. The performance of a vibratory shear-enhanced process (VSEP) combined with an appropriate membrane unit for the treatment of simulated or industrial tannery wastewaters. 4. A method for the analysis of thyroid hormones by liquid chromatography-mass spectrometry that was used for the dissolution testing of single- and dual-component thyroid hormone supplements via a two-stage biorelevant dissolution procedure. 5. A method involving the collection and determination of organic and inorganic gunshot residues on hands using online in-tube solid-phase microextraction (IT-SPME) coupled to miniaturized capillary liquid chromatography with diode array detection (CapLC-DAD) and scanning electron microscopy coupled to energy dispersion X-ray (SEM-EDX), respectively, for quantifying both residues. 6. The gas chromatographic retention behavior of 16 polycyclic aromatic hydrocarbons (PAHs) and alkylated PAHs on a new ionic liquid stationary phase, 1,12-di(tripropylphosphonium) dodecane bis(trifluoromethanesulfonyl)imide (SLB®-ILPAH) intended for the separation of PAH mixtures, which was compared with the elution pattern on more traditional stationary phases: a non-polar phenyl arylene (DB-5ms) and a semipolar 50% phenyl dimethyl siloxane (SLB PAHms) column. 7. The Multiple-Stage Precursor Ion Separation and High Resolution Mass Spectrometry toward Structural Characterization of 2,3-Diacyltrehalose Family from Mycobacterium tuberculosis 8. The use of micellar electrokinetic chromatography (MEKC) for studying the hydrophobic character of modified Monomethyl Auristatin E derivatives, as Novel Candidates for the Design of Antibody–Drug Conjugates, which are promising state-of-the-art biopharmaceutical drugs for selective drug-delivery applications and the treatment of diseases such as cancer. 9. The use of recycled diatomaceous earth as the extraction phase in solid phase microextraction (SPME) technique for the determination of polycyclic aromatic hydrocarbons (PAHs) in river water samples, with separation/detection performed by gas chromatography-mass spectrometry (GC-MS).

Research & information: general --- recycled diatomaceous earth --- solid phase microextraction --- polycyclic aromatic hydrocarbons --- gas chromatography-mass spectrometry --- antibody-drug conjugate --- biopharmaceutical --- cytotoxicity --- hydrophobicity --- micellar electrokinetic chromatography --- tandem mass spectrometry --- linear ion trap --- glycolipid --- diacyltrehalose --- Mycobacterium tuberculosis --- bisphosphonates --- risedronate --- zoledronate --- tiludronate --- ZIC-HILIC --- PDA --- quantitation --- tablets --- ionic liquid stationary phase --- gas chromatography --- chromatographic selectivity --- alkylated polycyclic aromatic hydrocarbons (alkylated PAHs) --- diphenylamine --- gunshot residues --- hands --- dry cotton swab --- in-tube solid-phase extraction --- capillary liquid chromatography --- SEM-EDX --- thyroid --- dissolution --- liquid chromatography-mass spectrometry --- membrane filtration-treatment --- membrane type-operation --- membrane fouling mechanism --- tannery industrial wastewater --- vibratory shear-enhanced process (VSEP) --- tricyclic antidepressants (TCAs) --- sample treatment --- biological fluids --- UV filters --- matrix solid-phase dispersion --- μ-MSPD --- miniaturized extraction technique --- GC–MS/MS --- cosmetic analysis --- personal care products --- fragrance allergens --- preservatives --- plasticizers --- synthetic musks

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Five years of Separations are celebrated by a collection of ten feature articles: one review and nine research articles on topics of current interest. Applications of Gas Chromatography for the Analysis of Tricyclic Antidepressants in Biological Matrices are presented focusing on novel extraction techniques and novel materials used for sample preparation due to the great demand for method development for the determination of TCAs in biofluids, especially for therapeutic drug monitoring. Original research articles include the following: 1. Insights into the Mechanism of Separation of Bisphosphonates by Zwitterionic Hydrophilic Interaction Liquid Chromatography: Application to the Quantitation of Risedronate in Pharmaceuticals. 2. A method based on micro-matrix solid-phase dispersion (μ-MSPD) followed by gas-chromatography tandem mass spectrometry (GC–MS/MS), developed to analyze UV filters in personal care products. 3. The performance of a vibratory shear-enhanced process (VSEP) combined with an appropriate membrane unit for the treatment of simulated or industrial tannery wastewaters. 4. A method for the analysis of thyroid hormones by liquid chromatography-mass spectrometry that was used for the dissolution testing of single- and dual-component thyroid hormone supplements via a two-stage biorelevant dissolution procedure. 5. A method involving the collection and determination of organic and inorganic gunshot residues on hands using online in-tube solid-phase microextraction (IT-SPME) coupled to miniaturized capillary liquid chromatography with diode array detection (CapLC-DAD) and scanning electron microscopy coupled to energy dispersion X-ray (SEM-EDX), respectively, for quantifying both residues. 6. The gas chromatographic retention behavior of 16 polycyclic aromatic hydrocarbons (PAHs) and alkylated PAHs on a new ionic liquid stationary phase, 1,12-di(tripropylphosphonium) dodecane bis(trifluoromethanesulfonyl)imide (SLB®-ILPAH) intended for the separation of PAH mixtures, which was compared with the elution pattern on more traditional stationary phases: a non-polar phenyl arylene (DB-5ms) and a semipolar 50% phenyl dimethyl siloxane (SLB PAHms) column. 7. The Multiple-Stage Precursor Ion Separation and High Resolution Mass Spectrometry toward Structural Characterization of 2,3-Diacyltrehalose Family from Mycobacterium tuberculosis 8. The use of micellar electrokinetic chromatography (MEKC) for studying the hydrophobic character of modified Monomethyl Auristatin E derivatives, as Novel Candidates for the Design of Antibody–Drug Conjugates, which are promising state-of-the-art biopharmaceutical drugs for selective drug-delivery applications and the treatment of diseases such as cancer. 9. The use of recycled diatomaceous earth as the extraction phase in solid phase microextraction (SPME) technique for the determination of polycyclic aromatic hydrocarbons (PAHs) in river water samples, with separation/detection performed by gas chromatography-mass spectrometry (GC-MS).

recycled diatomaceous earth --- solid phase microextraction --- polycyclic aromatic hydrocarbons --- gas chromatography-mass spectrometry --- antibody-drug conjugate --- biopharmaceutical --- cytotoxicity --- hydrophobicity --- micellar electrokinetic chromatography --- tandem mass spectrometry --- linear ion trap --- glycolipid --- diacyltrehalose --- Mycobacterium tuberculosis --- bisphosphonates --- risedronate --- zoledronate --- tiludronate --- ZIC-HILIC --- PDA --- quantitation --- tablets --- ionic liquid stationary phase --- gas chromatography --- chromatographic selectivity --- alkylated polycyclic aromatic hydrocarbons (alkylated PAHs) --- diphenylamine --- gunshot residues --- hands --- dry cotton swab --- in-tube solid-phase extraction --- capillary liquid chromatography --- SEM-EDX --- thyroid --- dissolution --- liquid chromatography-mass spectrometry --- membrane filtration-treatment --- membrane type-operation --- membrane fouling mechanism --- tannery industrial wastewater --- vibratory shear-enhanced process (VSEP) --- tricyclic antidepressants (TCAs) --- sample treatment --- biological fluids --- UV filters --- matrix solid-phase dispersion --- μ-MSPD --- miniaturized extraction technique --- GC–MS/MS --- cosmetic analysis --- personal care products --- fragrance allergens --- preservatives --- plasticizers --- synthetic musks

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The book gives an overview on the progress that has been made in the treatment of acute lymphoblastic leukemia (ALL), of acute and chronic myeloid leukemia (AML, CML) and of juvenile myelomonocytic leukemia (JMML). Leukemia is the most common malignant disease in children, and 80% of patients are diagnosed with ALL and 15–20% with AML, whereas CML and JMML are rather rare. Although ALL was considered an incurable disease until the early 1960s, with the availability of cytotoxic drugs and the start of clinical multicenter studies, ALL has become an almost curable disease with a survival rate exceeding 90 % in high-income countries. These impressive results have mainly been achieved by a deeper understanding of the genomic landscape of the disease and the introduction of risk stratifications based on genetic features and response to chemotherapy as determined by the presence or absence of minimal residual disease (MRD). Immunotherapies including bispecific T-cell Engagers (BiTEs), Chimeric Antigen Receptor (CAR) T cells, monoclonal antibodies and improvements in the outcome of allogeneic stem cell transplantation (HSCT) have shown impressive results in chemorefractory or relapsed patients, and it is anticipated that the cure rate can be further increased. For countries with less resources, therapies have to be adapted to increase survival as well. This book also updates on the progress made in the treatment of AML. As in ALL, risk classification based on genetic factors and response to chemotherapy is most important for therapy guidance. The book also provides updates and guidance for the treatment of CML and JMML.

Research & information: general --- Chemistry --- acute lymphoblastic leukemia --- pediatric --- advances --- diagnosis --- treatment --- immunotherapy --- bispecific T-cell engager (BiTE) --- BCP-ALL --- leukemia --- TRAIL --- antibody --- Fc-engineering --- xenograft --- CD19 --- juvenile myelomonocytic leukemia --- RAS signaling --- hematopoietic stem cell transplantation --- 5-azacitidine --- myelodysplastic/myeloproliferative disorders --- targeted therapy --- ADC --- antibody-drug conjugate --- pediatric leukemia --- ALL --- AML --- allogeneic stem cell transplantation --- acute myeloid leukemia --- minimal residual disease --- conditioning regimen --- alternative donors --- B-ALL --- DUX4 --- IKZF1 --- PAX5 --- Ph-like --- ZNF384 --- NUTM1 --- T-ALL --- NOTCH1 --- BCL11B --- transcriptome --- genome --- chronic myeloid leukemia --- CML --- tyrosine kinase inhibitor --- immunizations --- COVID-19 --- childhood acute lymphoblastic leukemia --- low-risk ALL --- risk-stratified treatment --- treatment related toxicity --- L-asparaginase --- acute pancreatitis --- polymorphism --- SNV --- ABCC4 --- CFTR --- other extramedullary relapse --- lymphoblastic leukemia --- children --- prognosis --- evolution of CAR T cells --- FDA-approved CAR products --- TcR versus CAR --- limitations and complications of CAR T cell therapy --- future directions of CAR T cell therapy --- acute lymphoblastic leukemia --- pediatric --- advances --- diagnosis --- treatment --- immunotherapy --- bispecific T-cell engager (BiTE) --- BCP-ALL --- leukemia --- TRAIL --- antibody --- Fc-engineering --- xenograft --- CD19 --- juvenile myelomonocytic leukemia --- RAS signaling --- hematopoietic stem cell transplantation --- 5-azacitidine --- myelodysplastic/myeloproliferative disorders --- targeted therapy --- ADC --- antibody-drug conjugate --- pediatric leukemia --- ALL --- AML --- allogeneic stem cell transplantation --- acute myeloid leukemia --- minimal residual disease --- conditioning regimen --- alternative donors --- B-ALL --- DUX4 --- IKZF1 --- PAX5 --- Ph-like --- ZNF384 --- NUTM1 --- T-ALL --- NOTCH1 --- BCL11B --- transcriptome --- genome --- chronic myeloid leukemia --- CML --- tyrosine kinase inhibitor --- immunizations --- COVID-19 --- childhood acute lymphoblastic leukemia --- low-risk ALL --- risk-stratified treatment --- treatment related toxicity --- L-asparaginase --- acute pancreatitis --- polymorphism --- SNV --- ABCC4 --- CFTR --- other extramedullary relapse --- lymphoblastic leukemia --- children --- prognosis --- evolution of CAR T cells --- FDA-approved CAR products --- TcR versus CAR --- limitations and complications of CAR T cell therapy --- future directions of CAR T cell therapy

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This book is a compendium of scientific articles submitted to a Special Issue of International Journal of Molecular Sciences, fostered by MDPI and curated by Dr. Annamaria Sandomenico and Dr. Menotti Ruvo from the Institute of Biostructure and Bioimaging of the National Research Council. All articles underwent a rigorous peer review and were selected to highlight the properties that make monoclonal antibodies and their functional fragments some of the most useful and versatile assets in therapy and diagnosis.

Technology: general issues --- porcine deltacoronavirus --- nucleocapsid --- monoclonal antibodies --- neurodegenerative disorders --- affibody molecules --- blood–brain barrier --- receptor-mediated transcytosis --- transferrin receptor --- AL amyloidosis --- CD38 --- anti-CD38 MoAb --- Daratumumab --- Isatuximab --- myeloma --- BCMA --- bispecific T-cell engager --- antibody-drug conjugates --- chimeric antigen receptor T-cells --- belantamab mafodotin --- idecabtagene vicleucel --- JNJ-68284528 --- Mabs --- Antibody-Drug Conjugate --- cancer therapy --- drug targeting --- payload --- cross-linking --- antibody fragment --- Fab --- scFv --- E. coli --- YKL-40 --- CHI3L1 --- monoclonal antibody --- phage display --- lung metastasis --- prostate-specific membrane antigen --- in vivo imaging --- prostate cancer --- glutamate carboxypeptidase II --- NAALADase --- immunization --- antibody --- protocol --- guinea pig --- cDNA --- chimeric antigen receptor (CAR T) --- universal CAR T --- modular CAR T --- universal immune receptor --- CAR adaptor --- adoptive immunotherapy --- split CAR --- bispecific --- polyspecificity --- pharmacokinetics --- solubility --- aggregation --- viscosity --- developability --- stability --- affinity --- specificity --- protein engineering --- self-association --- non-specific binding --- immunogenicity --- antibody fragments --- single chain --- amyloid --- oligomer --- neurotoxicity --- NUsc1 --- porcine deltacoronavirus --- nucleocapsid --- monoclonal antibodies --- neurodegenerative disorders --- affibody molecules --- blood–brain barrier --- receptor-mediated transcytosis --- transferrin receptor --- AL amyloidosis --- CD38 --- anti-CD38 MoAb --- Daratumumab --- Isatuximab --- myeloma --- BCMA --- bispecific T-cell engager --- antibody-drug conjugates --- chimeric antigen receptor T-cells --- belantamab mafodotin --- idecabtagene vicleucel --- JNJ-68284528 --- Mabs --- Antibody-Drug Conjugate --- cancer therapy --- drug targeting --- payload --- cross-linking --- antibody fragment --- Fab --- scFv --- E. coli --- YKL-40 --- CHI3L1 --- monoclonal antibody --- phage display --- lung metastasis --- prostate-specific membrane antigen --- in vivo imaging --- prostate cancer --- glutamate carboxypeptidase II --- NAALADase --- immunization --- antibody --- protocol --- guinea pig --- cDNA --- chimeric antigen receptor (CAR T) --- universal CAR T --- modular CAR T --- universal immune receptor --- CAR adaptor --- adoptive immunotherapy --- split CAR --- bispecific --- polyspecificity --- pharmacokinetics --- solubility --- aggregation --- viscosity --- developability --- stability --- affinity --- specificity --- protein engineering --- self-association --- non-specific binding --- immunogenicity --- antibody fragments --- single chain --- amyloid --- oligomer --- neurotoxicity --- NUsc1